查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953776

軟骨再生市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、治療方式、應用、地區和競爭格局分類，2021-2031年）

Cartilage Regeneration Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment Modality (Cell-Based, Non-Cell Based ), By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球軟骨再生市場預計將從 2025 年的 17.5 億美元成長到 2031 年的 45.7 億美元，複合年成長率為 17.34%。

該市場涵蓋細胞療法、組織支架和生長因子等醫療解決方案，旨在修復受損的關節軟骨。推動這一成長的關鍵因素包括全球骨關節炎負擔的加重和運動創傷發生率的上升。此外，越來越多的患者傾向於選擇關節保留療法而非全關節置換術，這也支撐了對這些修復性治療方法的需求。國際軟骨再生與關節保護協會 (ICRPS) 的報告顯示，其全球病患登記庫的活躍參與者人數在 2024 年比前一年成長了 100% 以上，這體現了臨床上日益成長的興趣。

市場概覽
預測期 2027-2031
市場規模：2025年 17.5億美元
市場規模：2031年 45.7億美元
複合年成長率：2026-2031年 17.34%
成長最快的細分市場 纖維軟骨
最大的市場 北美洲

然而，報銷方面的挑戰嚴重阻礙了市場的廣泛擴張。新型再生醫學療法的高昂費用往往無法獲得公共或私人保險公司的全額報銷，從而構成了准入門檻。這種支付模式的不確定性令醫療服務提供者望而卻步，並限制了患者獲得這些治療方法，進而限制了新興生物療法的商業性擴充性。

市場促進因素

全球老齡人口的成長以及由此導致的骨關節炎盛行率上升，正成為全球軟骨再生市場發展的根本催化劑。隨著人口老化的加劇，關節的累積機械磨損導致退化性疾病激增，使得人們迫切需要修復性干預措施，而非安寧療護。這種人口結構的變化與患者對能夠延緩或避免全置換術的生物製劑的需求成長直接相關。根據美國疾病管制與預防中心（CDC）於2024年1月發布的《骨關節炎》概況介紹，美國約有3,300萬成年人患有骨關節炎。如此沉重的疾病負擔凸顯了開發有效再生藥物以維持長期關節健康和活動能力的緊迫性。

同時，政府和私人對再生醫學研究的投入不斷增加，顯著提升了該領域的技術能力。資金的湧入推動了先進組織工程計劃和新型支架的研發，而這些項目和支架先前因高昂的研發成本而受阻。例如，在2024年9月題為「杜克大學獲得高達3,300萬美元聯邦資金用於開發骨關節炎療法」的新聞稿中，杜克大學健康中心宣布其研究團隊已獲得美國高級研究計劃署（ARPA-H）的一項重大津貼，用於開發改良的關節再生解決方案。這項資金支持對於將基礎研究轉化為具有商業性價值的產品至關重要。儘管面臨資金障礙，Vericel公司仍展現出巨大的市場潛力。該公司在2024年2月發布的「2023年第四季及全年財務表現」報告中指出，其軟骨修復植入MACI的淨銷售額成長了25%，達到1.648億美元。

市場挑戰

新型再生醫學技術的高成本，加上保險覆蓋不足，嚴重阻礙了全球軟骨再生市場的擴張。細胞療法和組織支架等先進解決方案往往缺乏具體的報銷代碼，或被歸類在模糊的支付模式，為醫療機構帶來巨大的財務風險。這種不確定性使得醫院和診所不願採用這些治療方法，因為他們面臨拒付和支付金額不足以支付生物製藥高昂採購成本的風險。因此，患者主要只能自費接受治療，這阻礙了這些治療方法的商業性擴充性。

整形外科診療的經濟負擔進一步加劇了這個進入門檻。據美國整形外科醫師學會稱，美國醫療保險和醫療補助服務中心（CMS）將2024年醫療保險醫師收費標準轉換係數上年度降低了3.37%。整形外科服務標準報銷額的降低削弱了支持昂貴創新療法所需的財務空間。隨著醫療機構收入來源的減少，將高成本的軟骨再生技術納入標準治療方案的經濟可行性降低，直接阻礙了市場成長。

市場趨勢

微創關節關節鏡植入系統的廣泛應用正在從根本上改變市場格局，降低手術併發症風險，縮短患者復原時間。傳統的開放式關節手術需要較大的切口和較長的住院時間，而先進的關節鏡器械則可以透過微小的切口精準植入生物材料橋。這項技術進步，加上全球醫療模式向門診治療的轉變，正促使複雜的軟骨修復手術轉移到日間手術中心進行。 2025年5月，Vericel在其「2025會計年度第一季財報」中宣布，其MACI植入季度銷售額創下4,630萬美元的歷史新高。這一成長動能直接得益於該公司新推出的關節鏡植入系統已成功培訓了約400名外科醫生。

同時，異體即用型細胞療法的商業化正在克服自體移植手術的局限性，後者通常需要兩次手術和較長的細胞培養期。這些即用型解決方案利用供體來源的細胞或易於取得的羊膜組織，無需進行切片檢查採集，從而簡化了供應鏈並顯著降低了治療成本。這種擴充性透過為骨關節炎和軟骨缺損的治療提供「即用型」替代方案，推動了醫療服務提供者的採用。為了滿足這一市場需求，Organogenesis Holdings, Inc. 在 2025 年 11 月的「2025 會計年度第三季財報電話會議」上宣布，由於其產品系列在外科和運動醫學領域的持續擴張和應用，公司淨產品銷售額達到 1.505 億美元。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球軟骨再生市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（纖維軟骨、透明軟骨、彈性軟骨、其他）
    • 治療方法（細胞療法（軟骨細胞、移植、生長因子技術）、非細胞療法（組織支架、無細胞複合材料））
    • 依應用部位（膝蓋、脊椎、腳踝、髖部等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美軟骨再生市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲軟骨再生市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區軟骨再生市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲軟骨再生市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美軟骨再生市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球軟骨再生市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Osiris Therapeutics, Inc
  • Smith & Nephew Plc.
  • Vericel Corporation
  • Zimmer Biomet Holdings, Inc.
  • Medtronic Plc.
  • Stryker Corporation
  • Anika Therapeutics, Inc.
  • B. Braun SE
  • Orthocell Ltd.
  • Geistlich Pharma AG
  • Takeda Pharmaceutical Company Limited
  • CONMED Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23864

The Global Cartilage Regeneration Market is projected to expand from USD 1.75 Billion in 2025 to USD 4.57 Billion by 2031, reflecting a CAGR of 17.34%. This market comprises medical solutions such as cellular therapies, tissue scaffolds, and growth factors designed to repair damaged articular cartilage. Key drivers fueling this growth include the escalating global burden of osteoarthritis and the rising incidence of traumatic sports injuries. Additionally, a growing patient preference for joint preservation over total arthroplasty bolsters demand for these restorative interventions. Highlighting this increasing clinical interest, the International Cartilage Regeneration and Joint Preservation Society reported that active participation in its global patient registry rose by more than 100% in 2024 compared to the previous year.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.75 Billion
Market Size 2031USD 4.57 Billion
CAGR 2026-203117.34%
Fastest Growing SegmentFibro Cartilage
Largest MarketNorth America

However, broad market expansion is significantly impeded by reimbursement challenges. The high costs associated with novel regenerative procedures frequently lack adequate coverage from public and private insurance payers, establishing a financial barrier to entry. This ambiguity regarding payment models discourages healthcare providers and restricts patient access to these therapies, thereby limiting the commercial scalability of emerging biological solutions.

Market Driver

The growing global geriatric population and the associated prevalence of osteoarthritis act as fundamental catalysts for the Global Cartilage Regeneration Market. As the aging demographic increases, cumulative mechanical wear on articular joints leads to a surge in degenerative conditions, creating a critical need for restorative interventions rather than palliative care. This demographic shift correlates directly with rising patient demand for biological solutions capable of delaying or preventing total joint arthroplasty. According to the Centers for Disease Control and Prevention's 'Osteoarthritis' fact sheet from January 2024, approximately 33 million adults in the United States were estimated to have osteoarthritis, a substantial disease burden that underscores the urgency for effective regenerative therapies to maintain long-term joint health and mobility.

Concurrently, increased government and private funding for regenerative medicine research is significantly enhancing the sector's technological capabilities. Greater capital inflows facilitate the development of sophisticated tissue engineering projects and novel scaffolds that were previously hindered by high development costs. For instance, Duke Health announced in a September 2024 press release titled 'Duke Awarded Federal Funding up to $33 Million to Develop Osteoarthritis Therapies' that a research team secured a major grant from ARPA-H to create improved joint regeneration solutions. This financial support is pivotal for translating bench research into commercially viable products. Demonstrating the market's potential despite economic barriers, Vericel Corporation reported in its 'Fourth Quarter and Full-Year 2023 Financial Results' in February 2024 that net revenue for the MACI cartilage repair implant rose 25% to $164.8 million.

Market Challenge

The high cost of novel regenerative procedures, combined with inadequate insurance coverage, significantly hampers the expansion of the Global Cartilage Regeneration Market. Advanced solutions like cellular therapies and tissue scaffolds often lack specific reimbursement codes or fall into ambiguous payment models, creating substantial financial risk for healthcare providers. This uncertainty deters hospitals and clinics from adopting these therapies, as they face the risk of denied claims or insufficient payments that fail to cover the high acquisition costs of biological products. Consequently, patient access is restricted primarily to those capable of paying out-of-pocket, limiting the commercial scalability of these interventions.

The financial strain on orthopedic practices further exacerbates this barrier to entry. According to the American Association of Orthopaedic Surgeons, the Centers for Medicare & Medicaid Services implemented a 3.37% reduction in the Medicare Physician Fee Schedule conversion factor in 2024 compared to the prior year. This contraction in baseline reimbursement for orthopedic services erodes the economic margin necessary to support expensive, innovative treatments. As providers encounter tightening revenue streams, the financial viability of incorporating high-cost cartilage regeneration techniques into standard care pathways diminishes, directly stalling market growth.

Market Trends

The proliferation of Minimally Invasive Arthroscopic Delivery Systems is fundamentally reshaping the market by reducing surgical morbidity and accelerating patient recovery times. Unlike traditional open arthrotomy, which necessitates significant incisions and extended hospital stays, advanced arthroscopic instruments now enable the precise implantation of biologic scaffolds through portal-sized incisions. This technological evolution aligns with the global shift toward outpatient care, effectively moving complex cartilage restoration into ambulatory surgical centers. In May 2025, Vericel Corporation reported in its 'First Quarter 2025 Financial Results' record quarterly revenue for its MACI implant of $46.3 million, a growth trajectory directly supported by the successful training of approximately 400 surgeons on its newly launched arthroscopic delivery system.

Simultaneously, the Commercialization of Allogeneic Off-the-Shelf Cell Therapies is overcoming the logistical limitations of autologous procedures, which typically require two surgeries and extended cell culturing periods. By utilizing donor-derived cells or amniotic tissues available for immediate use, these off-the-shelf solutions eliminate the need for biopsy harvesting, thereby streamlining the supply chain and significantly reducing treatment costs. This scalability promotes provider adoption by offering a "ready-to-use" alternative for managing osteoarthritis and chondral defects. Validating this market demand, Organogenesis Holdings Inc. announced in its 'Third Quarter 2025 Earnings Call' in November 2025 that net product revenue reached $150.5 million, driven in part by the continued expansion and adoption of its surgical and sports medicine portfolio.

Key Market Players

  • Osiris Therapeutics, Inc
  • Smith & Nephew Plc.
  • Vericel Corporation
  • Zimmer Biomet Holdings, Inc.
  • Medtronic Plc.
  • Stryker Corporation
  • Anika Therapeutics, Inc.
  • B. Braun SE
  • Orthocell Ltd.
  • Geistlich Pharma AG
  • Takeda Pharmaceutical Company Limited
  • CONMED Corporation

Report Scope

In this report, the Global Cartilage Regeneration Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cartilage Regeneration Market, By Type

  • Fibro Cartilage
  • Hyaline Cartilage
  • Elastic Cartilage
  • Other

Cartilage Regeneration Market, By Treatment Modality

  • Cell-Based (Chondrocyte, Transplantation, Growth Factor Technology)
  • Non-Cell Based (Tissue Scaffolds, Cell-Free Composites)

Cartilage Regeneration Market, By Application

  • Knee
  • Spine
  • Ankle
  • Hip
  • Others

Cartilage Regeneration Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cartilage Regeneration Market.

Available Customizations:

Global Cartilage Regeneration Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cartilage Regeneration Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Fibro Cartilage, Hyaline Cartilage, Elastic Cartilage, Other)
    • 5.2.2. By Treatment Modality (Cell-Based (Chondrocyte, Transplantation, Growth Factor Technology), Non-Cell Based (Tissue Scaffolds, Cell-Free Composites))
    • 5.2.3. By Application (Knee, Spine, Ankle, Hip, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Cartilage Regeneration Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment Modality
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cartilage Regeneration Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Treatment Modality
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Cartilage Regeneration Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Treatment Modality
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Cartilage Regeneration Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Treatment Modality
        • 6.3.3.2.3. By Application

7. Europe Cartilage Regeneration Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment Modality
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cartilage Regeneration Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Treatment Modality
        • 7.3.1.2.3. By Application
    • 7.3.2. France Cartilage Regeneration Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Treatment Modality
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Cartilage Regeneration Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Treatment Modality
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Cartilage Regeneration Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Treatment Modality
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Cartilage Regeneration Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Treatment Modality
        • 7.3.5.2.3. By Application

8. Asia Pacific Cartilage Regeneration Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment Modality
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cartilage Regeneration Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Treatment Modality
        • 8.3.1.2.3. By Application
    • 8.3.2. India Cartilage Regeneration Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Treatment Modality
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Cartilage Regeneration Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Treatment Modality
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Cartilage Regeneration Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Treatment Modality
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Cartilage Regeneration Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Treatment Modality
        • 8.3.5.2.3. By Application

9. Middle East & Africa Cartilage Regeneration Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment Modality
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cartilage Regeneration Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Treatment Modality
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE Cartilage Regeneration Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Treatment Modality
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa Cartilage Regeneration Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Treatment Modality
        • 9.3.3.2.3. By Application

10. South America Cartilage Regeneration Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Treatment Modality
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cartilage Regeneration Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Treatment Modality
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia Cartilage Regeneration Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Treatment Modality
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina Cartilage Regeneration Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Treatment Modality
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cartilage Regeneration Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Osiris Therapeutics, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Smith & Nephew Plc.
  • 15.3. Vericel Corporation
  • 15.4. Zimmer Biomet Holdings, Inc.
  • 15.5. Medtronic Plc.
  • 15.6. Stryker Corporation
  • 15.7. Anika Therapeutics, Inc.
  • 15.8. B. Braun SE
  • 15.9. Orthocell Ltd.
  • 15.10. Geistlich Pharma AG
  • 15.11. Takeda Pharmaceutical Company Limited
  • 15.12. CONMED Corporation

16. Strategic Recommendations

17. About Us & Disclaimer